SR33805

• Description :

  SR33805 is a potent Ca2+ channel antagonist, with EC50s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca2+ channels. SR33805 can be used for the research of acute or chronic failing hearts[1][2].

• UNSPSC :

  12352005

• Target :

  Calcium Channel

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/sr33805.html

• Purity :

  99.78

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  O=S(C1=CC=C(OCCCN(C)CCC2=CC=C(OC)C(OC)=C2)C=C1)(C3=C(C(C)C)N(C)C4=C3C=CC=C4)=O

• Molecular Formula :

  C32H40N2O5S

• Molecular Weight :

  564.74

• References & Citations :

  [1]Romey G, et, al. Effects of two chemically related new Ca2+ channel antagonists, SR33557 (fantofarone) and SR33805, on the L-type cardiac channel. Eur J Pharmacol. 1994 Sep 22; 263 (1-2) : 101-5.|[2]Mou YA, et, al. Beneficial effects of SR33805 in failing myocardium. Cardiovasc Res. 2011 Aug 1; 91 (3) : 412-9.|[3]Hainaud P, et, al. The calcium inhibitor SR33805 reduces intimal formation following injury of the porcine carotid artery. Atherosclerosis. 2001 Feb 1; 154 (2) : 301-8.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  L-type calcium channel

• CAS Number :

  [121345-64-0]